To the Editor: An infrequently reported cutaneous complication of biologic treatment is onset localized scleroderma or morphea. Given increasing use therapy worldwide, it essential for health care providers to anticipate and manage potential adverse effects. This review aims summarize reports morphea development in patients receiving therapies targeting inflammatory pathways implicated psoriasi...

Background Morphea is a subtype of limited scleroderma characterized by atrophic changes. There are multiple treatment modalities for morphea, but all have success to restore atrophy. Objectives To evaluate the efficacy and safety paltelet rich plasma (PRP) skin changes in morphea such as (skin atrophy, dyspigmentation adnexal destruction) ultrasound Localized Scleroderma Cutaneous Assessment T...

Secondary mucin deposition in the skin is a common feature of lupus erythematosus and dermatomyositis. In scleroderma, it occurs uncommonly or in small amount. We describe a 7-year-old boy with progressive, linear, bound-down plaques involving the thighs, lower abdomen and back with no systemic involvement. Histopathology showed features of scleroderma with abundant mucin deposition in the reti...